tfeb activator Search Results


tfeb activator 1  (MedChemExpress)
94
MedChemExpress tfeb activator 1
BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB <t>activator</t> <t>1</t> (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.
Tfeb Activator 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tfeb+activator/TFEB+activator+1/pmc13216193-57-12-19
Average 94 stars, based on 1 article reviews
tfeb activator 1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
tfeb activator 1  (TargetMol)
N/A
   Buy from Supplier
paradoxical feeding activation of gut lipophagy via an fgf15-shp- tfeb axis limits postprandial lipids  (Kemper GmbH)
90
Kemper GmbH paradoxical feeding activation of gut lipophagy via an fgf15-shp- tfeb axis limits postprandial lipids
BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB <t>activator</t> <t>1</t> (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.
Paradoxical Feeding Activation Of Gut Lipophagy Via An Fgf15 Shp Tfeb Axis Limits Postprandial Lipids, supplied by Kemper GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tfeb+activator/paradoxical+feeding+activation+of+gut+lipophagy+via+an+fgf15+shp++tfeb+axis+limits+postprandial+lipids/pmc09434102__EMBJ___41___e109997___s001-125-7-18
Average 90 stars, based on 1 article reviews
paradoxical feeding activation of gut lipophagy via an fgf15-shp- tfeb axis limits postprandial lipids - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tfeb activator upregulator  (Proteostasis Therapeutics)
86
Proteostasis Therapeutics tfeb activator upregulator
BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB <t>activator</t> <t>1</t> (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.
Tfeb Activator Upregulator, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tfeb+activator/activator+tfeb+upregulator/pmc12360913-10-0-3
Average 86 stars, based on 1 article reviews
tfeb activator upregulator - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
tfeb activator 2  (MedChemExpress)
N/A
TFEB activator 2 is an orally active compound that can cross the blood-brain barrier. TFEB activator 2 can bind to the dopamine transporter (DAT). TFEB activator 2 promotes TFEB nuclear translocation and lysosome biogenesis by
   Buy from Supplier
tfeb activator 2  (TargetMol)
N/A
   Buy from Supplier
mouse tfeb activation kit by crispra  (OriGene)
N/A
Tfeb CRISPRa kit CRISPR gene activation of mouse transcription factor EB
   Buy from Supplier
tfeb crispr activation plasmid  (Santa Cruz Biotechnology)
N/A
CRISPR/Cas9 KO Plasmids consists of TFEB-specific 20 nt guide RNA sequences derived from the GeCKO (v2) library. For CRISPR gene knockout, gRNA sequences direct the Cas9 protein to induce a site-specific double strand break (DSB)
   Buy from Supplier
human tfeb activation kit by crispra  (OriGene)
N/A
TFEB CRISPRa kit CRISPR gene activation of human transcription factor EB
   Buy from Supplier
human tfeb transcription factor activity assay  (RayBiotech)
N/A
RayBio® Human TFEB Transcription Factor Activity Assay. This assay uses a dsDNA coated plate with canonical TFEB binding sequences to semi-quantitatively detect active TFEB in lysates or nuclear extracts. Only available in North America.
   Buy from Supplier
tfeb activator 3  (TargetMol)
N/A
   Buy from Supplier
tfeb lentiviral activation particles  (Santa Cruz Biotechnology)
N/A
CRISPR/Cas9 KO Plasmids consists of TFEB-specific 20 nt guide RNA sequences derived from the GeCKO (v2) library. For CRISPR gene knockout, gRNA sequences direct the Cas9 protein to induce a site-specific double strand break (DSB)
   Buy from Supplier

Image Search Results


BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB activator 1 (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.

Journal: Frontiers in Pharmacology

Article Title: Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation

doi: 10.3389/fphar.2026.1763828

Figure Lengend Snippet: BBM suppresses the SIRT1-TFEB axis at the protein level. (A,B) Western blot analysis of SIRT1 and TFEB protein levels in cells treated with BBM at indicated concentrations (A) or for indicated times (B) . (C) Immunofluorescence analysis of TFEB subcellular localization. Cells were treated with BBM (5 μM) or TFEB activator 1 (0.5 μM) for 24 h and stained for TFEB (red) and DAPI (blue). Scale bar, 5 μm. (D) Intracellular NAD + levels and NAD + /NADH ratio in cells treated with BBM (2.5, 5, 10 μM) for 24 h. All values represent the mean ± SD (n = 3), * p < 0.05, ** p < 0.01. (E) Transcriptomic analysis of differentially expressed genes in SMMC-7721 cells after BBM (5 μM) treatment for 24 h. (F) Reactome pathway enrichment analysis of downregulated gene. (G) Western blot analysis of OXPHOS components (MT-ND4, MT-ND4L) in cells treated with BBM (0-10 μM) for 24 h. (H) Molecular docking analysis showing the predicted binding mode of BBM with ERRα. BBM is shown in green sticks, and hydrogen bonds are indicated as yellow dashed lines.

Article Snippet: Sorafenib (HY-10201), Baflomycin A1 (HY-100558), chloroquine (HY-17589A), rapamycin (AY-22989), resveratrol (HY-16561), and TFEB activator 1 (HY-135825) were purchased from MedChemExpress (Princeton, NJ, USA).

Techniques: Western Blot, Immunofluorescence, Staining, Binding Assay

SIRT1 activation rescues BBM-induced autophagy blockade. (A,B) Western blot analysis of SIRT1, TFEB, lysosomal proteins (CTSB, CTSD, RAB7), and autophagy flux markers (p62, LC3) in cells treated with BBM (5 μM) in the presence or absence of the SIRT1 agonist Resveratrol (Res, 10 μM) or the TFEB agonist TFEB activator 1 (0.5 μM) for 24 h. Data are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01 vs. control; # p < 0.05, ## p < 0.01 vs. BBM-only group.

Journal: Frontiers in Pharmacology

Article Title: Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation

doi: 10.3389/fphar.2026.1763828

Figure Lengend Snippet: SIRT1 activation rescues BBM-induced autophagy blockade. (A,B) Western blot analysis of SIRT1, TFEB, lysosomal proteins (CTSB, CTSD, RAB7), and autophagy flux markers (p62, LC3) in cells treated with BBM (5 μM) in the presence or absence of the SIRT1 agonist Resveratrol (Res, 10 μM) or the TFEB agonist TFEB activator 1 (0.5 μM) for 24 h. Data are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01 vs. control; # p < 0.05, ## p < 0.01 vs. BBM-only group.

Article Snippet: Sorafenib (HY-10201), Baflomycin A1 (HY-100558), chloroquine (HY-17589A), rapamycin (AY-22989), resveratrol (HY-16561), and TFEB activator 1 (HY-135825) were purchased from MedChemExpress (Princeton, NJ, USA).

Techniques: Activation Assay, Western Blot, Control